Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
View Patent ↗The present invention is generally directed to an oral pharmaceutical tablet composition comprising a sulfate salt, for example, sodium sulfate, wherein the composition is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion. The present invention is further directed to use of such oral pharmaceutical tablet formulations to induce laxation or to treat or prevent constipation.
1. An oral pharmaceutical tablet composition comprising at least one sulfate salt,
wherein the tablet is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion,
wherein the tablet comprises sodium sulfate, and
wherein less than about 5% by weight of sodium sulfate in the tablet comprises sodium sulfate particles less than about 150 μm and greater than about 1000 μm.
2. The oral pharmaceutical tablet composition of claim 1 , wherein the tablet exhibits at least one of the following features:
(i) disintegrates in water at about 2° C. or greater in less than about 150 seconds;
(ii) disintegrates in water at about 8° C. or greater in less than about 90 seconds;
(iii) disintegrates in water at about 5° C. or greater in less than about 120 seconds; or
(v) does not disintegrate in the mouth in less than about 60 seconds upon direct oral ingestion.
3. The oral pharmaceutical tablet of claim 1 , wherein the tablet disintegrates in water at about 2° C. or greater in less than about 150 seconds, and wherein the tablet does not disintegrate in the mouth in less than about 30 seconds upon direct oral ingestion.
4. The oral pharmaceutical tablet of claim 1 , further comprising potassium sulfate and/or magnesium sulfate.
5. The oral pharmaceutical tablet of claim 1 , wherein the tablet comprises at least about 60%, 65%, 70%, 75%, 80%, 85% or 90% by weight of a sulfate salt selected from the group consisting of sodium sulfate, potassium sulfate, magnesium sulfate and combinations thereof.
6. The oral pharmaceutical tablet of claim 1 , wherein the tablet has a weight of between about 1000 mg and about 2500 mg, about 1500 mg and about 2000 mg, or about 1700 mg and about 1900 mg; or has a weight of about 1800 mg.
7. The oral pharmaceutical tablet of claim 1 , wherein the tablet comprises a coating, optionally comprising a copolymer of polyvinyl alcohol and polyethylene glycol.
8. The oral pharmaceutical tablet of claim 1 , wherein the tablet comprises at least one excipient selected from the group consisting of a disintegrant, a binder, a glidant, a lubricant, and combinations thereof.
9. The oral pharmaceutical tablet of claim 8 , wherein the tablet is characterized by at least one of the following features:
(a) wherein the disintegrant is (i) selected from the group consisting of povidone, crosslinked polyvinylpyrrolidone, sugar, sucrose, dextrose, mannitol, and a combination thereof; (ii) a combination of mannitol and povidone; or (iii) crosslinked polyvinylpyrrolidone;
(b) wherein the binder is selected from the group consisting of polyethylene glycol, PEG3350, PEG8000 and combinations thereof;
(c) wherein the glidant is fumed silica; or
(d) wherein the lubricant is selected from the group consisting of magnesium stearate, sodium stearyl fumarate, and combinations thereof.
10. The oral pharmaceutical tablet of claim 8 , wherein the total excipient level is less than about 40%, 35%, 30% or 25% by weight of the tablet.
11. The oral pharmaceutical tablet of claim 1 , wherein the tablet comprises at least about 70% by weight of a sulfate salt selected from the group consisting of sodium sulfate, potassium sulfate, magnesium sulfate and combinations thereof.
12. The oral pharmaceutical tablet of claim 1 , wherein the tablet comprises at least about 70% by weight of sodium sulfate and potassium sulfate.
13. The oral pharmaceutical tablet of claim 1 , wherein the tablet comprises at least about 40%, 45%, 50%, 55%, 57%, 60% or 65% by weight of sodium sulfate.
14. The oral pharmaceutical tablet of claim 1 , wherein the tablet comprises between about 40% and about 65%, or between about 50% and about 60% by weight of sodium sulfate.
15. The oral pharmaceutical tablet of claim 1 , wherein less than about 5% by weight of sodium sulfate in the tablet comprises sodium sulfate particles less than about 200 pm, 250 pm or 300 pm and sodium sulfate particles greater than about 700 pm, 750 pm, 800 pm, or 900 pm.
16. The oral pharmaceutical tablet of claim 1 , wherein less than about 5% by weight of sodium sulfate in the tablet comprises sodium sulfate particles less than about 150 pm and greater than about 700 pm.
17. The oral pharmaceutical tablet of claim 1 , wherein less than about 5% by weight of sodium sulfate in the tablet comprises sodium sulfate particles less than about 300 pm and greater than about 700 pm.
18. The oral pharmaceutical tablet of claim 1 , wherein about 96%, 97%, 98%, or 99% by weight of sodium sulfate in the tablet comprises sodium sulfate particles that are greater than about 150 pm, 200 pm, 250 pm or 300 pm and less than about 700 pm, 750 pm, 800 pm, 900 pm or 1000 pm.
19. The oral pharmaceutical tablet of claim 1 , wherein at least about 99% by weight of sodium sulfate in the tablet comprises sodium sulfate particles that are greater than about 150 pm, 200 pm, 250 pm or 300 pm and less than about 700 pm, 750 pm, 800 pm, 900 pm or 1000 pm.
20. The oral pharmaceutical tablet of claim 1 , wherein at least about 99% by weight of sodium sulfate in the tablet comprises sodium sulfate particles that are greater than about 150 pm and less than about 700 pm.
21. The oral pharmaceutical tablet of claim 1 , wherein at least about 99% by weight of sodium sulfate in the tablet comprises sodium sulfate particles that are greater than about 300 pm and less than about 700 pm.
22. An oral pharmaceutical tablet, comprising sodium sulfate and potassium sulfate,
wherein the tablet is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion,
wherein the tablet disintegrates in water at about 2° C. or greater in less than about 150 seconds,
wherein the tablet does not disintegrate in the mouth in less than about 30 seconds upon direct oral ingestion,
wherein the tablet comprises a coating,
wherein less than about 5% by weight of sodium sulfate in the tablet comprises sodium sulfate particles less than about 150 μm and greater than about 1000 μm.
23. The oral pharmaceutical tablet of claim 22 , wherein the tablet is characterized by at least one of the following features:
(i) wherein the tablet comprises at least about 70% by weight of sodium sulfate and potassium sulfate; and
(ii) wherein the tablet comprises a disintegrant.
24. A method of preparing the oral pharmaceutical tablet of claim 1 , the method comprising the steps of
(a) blending at least one sulfate salt and at least one excipient; and
(b) compressing the resulting blend into a tablet.
25. The method of claim 24 , wherein the step of blending comprises blending a batch of sodium sulfate, wherein less than about 5% by weight of the batch of sodium sulfate comprises sodium sulfate particles less than about 150 μm and greater than about 700 μm.
26. The method of claim 24 , further comprising coating the tablet.
27. The method of claim 24 , further comprising substantially removing sodium sulfate particles less than about 150 μm and greater than about 700 μm prior to blending.
28. The method of claim 24 , wherein the excipient is selected from the group consisting of a disintegrant, a binder, a glidant, a lubricant, and combinations thereof.
29. A method for inducing laxation in a subject, the method comprising administering to the subject at least one oral pharmaceutical tablet of claim 1 , thereby inducing laxation in the subject.
30. The method of claim 29 , wherein the tablet is swallowed directly by the subject.
31. The method of claim 29 , wherein the step of administering the tablet comprises orally ingesting an aqueous dispersion of the tablet.
32. The method of claim 29 , wherein the method induces laxation without inducing a clinically significant electrolyte shift in the subject.
33. The method of claim 29 , wherein the subject is administered 2, 3, 4 or 5 oral pharmaceutical tablets.
34. A method for preventing or treating constipation in a subject, the method comprising administering to the subject at least one oral pharmaceutical tablet of claim 1 , thereby treating or preventing constipation in the subject.
35. The method of claim 34 , wherein the method treats or prevents constipation without inducing a clinically significant electrolyte shift in the subject.